Featured Articles and Interviews
More Featured Articles and Inverviews
Press Releases
More Press Releases
Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's products under pipeline are GB-102, for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME; GB-103; and GB-401.